Shareholder Alert: The Ademi Firm investigates whether LAVA Therapeutics N.V. is obtaining a Fair Price for its Public Shareholders in the Amendment to the Purchase Agreement

Core Points - The Ademi Firm is investigating Lava (Nasdaq: LVTX) for potential breaches of fiduciary duty and other legal violations related to its transaction with XOMA Royalty [1] - Lava shareholders will receive an initial cash amount of $1.04 per share, which is lower than the previously agreed range of $1.16 to $1.24, along with a non-transferable contingent value right [2] - The minimum net-cash closing condition for the transaction has been amended from $31.5 million to $24.5 million [2] - The transaction agreement restricts competing bids for Lava by imposing significant penalties, raising concerns about the Lava board's fulfillment of fiduciary duties to shareholders [3]